| Issue Date | Title | Author(s) |
| 2018-02-01 | Targeted iron nanoparticles with platinum-(IV) prodrugs and anti-EZH2 siRNA show great synergy in combating drug resistance in vitro and in vivo | Yu, C; Ding, B; Zhang, X; Deng, X; Deng, K; Cheng, Z; Xing, B; Jin, D; Ma, P; Lin, J |
| 2015-08-03 | Formulation of Biologically-Inspired Silk-Based Drug Carriers for Pulmonary Delivery Targeted for Lung Cancer | Kim, SY; Naskar, D; Kundu, SC; Bishop, DP; Doble, PA; Boddy, AV; Chan, HK; Wall, IB; Chrzanowski, W |
| 1996-05-15 | Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer | Hansen, RM; Ryan, L; Anderson, T; Krzywda, B; Quebbeman, E; Benson, A; Haller, DG; Tormey, DC |
| 1987-01-01 | A random phase II study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma: An ECOG study | Falkson, G; Ryan, LM; Johnson, LA; Simson, IW; Coetzer, BJ; Carbone, PP; Creech, RH; Schutt, AJ |
| 2022-05 | Toxicity assessments and transcriptional effects of monofunctionalized Pt(II) complex under dark and light irradiation condition in Caenorhabditis elegans. | Chong, H; Fang, S; Yang, D; Tan, C; Wei, J; Chang, S-H; Fan, H; Yao, H; Qin, A; Shao, H; Zhang, Y; Leng, J; Su, D; Wang, C; Li, H |
| 2021-07-05 | BODIPY-Appended Pt(II) Complexes with High Toxicities and Anti-chemoresistance Performances in a Cisplatin Resistant In Vivo Model. | Chong, H; Tan, C; Fang, S; Chen, X; Tao, Q; Yuan, X; Li, J; Zhai, C; Fei, C; Yang, D; Fan, H; Shao, H; Qin, A; Wang, G; Shi, Z; Z'hang, T; Yao, H; Li, H; Wang, C |
| 2016-10 | Serum thioredoxin reductase is highly increased in mice with hepatocellular carcinoma and its activity is restrained by several mechanisms. | Zhang, L; Cheng, Q; Zhang, L; Wang, Y; Merrill, GF; Ilani, T; Fass, D; Arnér, ESJ; Zhang, J |
